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Open access under CC BY license.The power of fruit fly genetics is being deployed against
some of the most intractable and economically signifi-
cant problems in modern medicine, the neurodegenera-
tive diseases. Fly models of Alzheimer’s disease can be
exposed to the rich diversity of biological techniques
that are available to the community and are providing
new insights into disease mechanisms, and assisting in
the identification of novel targets for therapy. Similar
approaches might also help us to interpret the results of
genome-wide association studies of human neurode-
generative diseases by allowing us to triage gene ‘‘hits’’
according to whether a candidate risk factor gene has a
modifying effect on the disease phenotypes in fly model
systems.
Biological homologies allow us to successfully model
aspects of Alzheimer’s disease in the fly
Many Alzheimer’s disease (AD) researchers use animal
models to gain insights into the pathogenic processes that
occur in patients’ brains. In this reviewwewill discuss why
Drosophila melanogaster is a particularly powerful plat-
form (Figure 1) and what we have learned from AD
research in the fly. We will then discuss how the fly could
become a tool in the interpretation of a new generation of
human genetic studies.
Our faith in animal modelling is underpinned by a
profound core of functional similarity that spans the phy-
logenetic classes. Indeed the degree of biological conserva-
tion from yeast to humans has surprised many
investigators and is one of the most impressive findings
to emerge fromcomparative genomics.Whereas in thepre-
genome era we struggled to find similarities between
organisms, now the biologist’s burden is to define how
such genetically similar organisms turn out so differently.
Taking the number of genes as a crude measure of com-
plexity, then the fly, Drosophila (13,767 genes) [1], is only
slightly less complex than humans, who are now thought
to have about 19,599 genes [2,3]. Bioinformatic
approaches yield a critical core of biological similarity,
and at the top of the list are the transcription factors and
their target, non-coding DNA sequences [4]. These genes
and DNA sequences are profoundly conserved across mul-
ticellular organisms; it has been said that at this level
there has been precious little evolution since the appear-Corresponding author: Crowther, D.C. (dcc26@cam.ac.uk)
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also highly conserved across evolutionary time, including
potential pharmaceutical targets such as the protein
kinases and the homeobox domain proteins that play
key roles in multicellular organisms [1]. This core of
functionally essential genes is shared by both vertebrates
and invertebrates, thus providing an explanation for why
nearly 70% of human disease-causing genes have ortho-
logues in the fly [1], and a similar proportion can be found
in another invertebrate model system, the nematode
worm, Caenorhabditis elegans [6]. It is likely that such
conserved networks of interacting proteins and genes will
respond in a similarway to a particular insultwhether in a
human or an invertebrate context (Box 1).
Although the specific details of protein–protein inter-
actions can vary between insect and human, the degree of
functional conservation can be surprising; of particular
relevance for the AD field is the conservation of the proteo-
lytic activity of g-secretase between flies and humans. In
humans it is proposed that AD is initiated by the dysfunc-
tional activities of two proteinases (g- and b-secretase) that
generate a series of aggregation-prone peptides called Ab
from their substrate, amyloid precursor protein (APP).
Excessive accumulation of Ab peptides is thought to induce
neuronal dysfunction and death. Conveniently,Drosophila
g-secretase can correctly process human APP, and a
further similarity is that flies harbour an endogenous
orthologue of APP called Appl (APP-like). Yet there is no
natural generation of Ab, as flies lack an equivalent of b-
secretase and because APPL diverges in sequence from
APP at the positions that constitute the Ab peptides.
Where generic physico-chemical interactions underpin a
disease process, for example the proposed disruption of
membrane integrity by protein aggregates, fly models
might provide an excellent paradigm for research [7–9].
This exciting group of proteinmisfolding or conformational
disorders includes the major human neurodegenerative
disorders, including Alzheimer’s, Parkinson’s, Hunting-
ton’s disease and forms of fronto-temporal dementia [10–
12].
Exposing molecular culprits
Although it is thought that AD pathology is initiated by the
accumulation and aggregation of Ab peptides [13], it seems
unlikely that this accounts for all the features of the
disease. Indeed, Ab might not be required to maintaind. doi:10.1016/j.tibs.2009.11.004 Available online 25 December 2009
Figure 1. The fly provides a powerful toolkit for investigating the pathogenesis of
AD. The range of AD model systems, and the fly phenotypes associated with them,
allow investigators to screen of genetic and pharmacological modifiers of disease
processes [32,36–40,43,44,47,58,77,88–95]. Several online resources are available
for exploring the topic in greater detail: FlyChip: Functional Genomics for
Drosophila (http://www.flychip.org.uk/) and NIG-Fly: National Institute of
Genetics (http://www.shigen.nig.ac.jp/fly/nigfly/about/aboutRnai.jsp).
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initiates a series of downstream events, including the
phosphorylation and subsequent aggregation of tau within
the cytoplasm. The combination of these Ab- and tau-
mediated [14] toxic events might result in the neuronal
dysfunction and death that characterize AD [14–16]. How-
ever, the precise identity of the toxic species and their
cellular targets remain elusive. Initial work on humanBox 1. Similarities between fly and human nervous systems
The biological similarities (otherwise known as orthologies)
between humans and Drosophila have been exploited with great
success in the field of neurodegenerative disease in general [78],
and in AD research in particular. The principal reason behind this is
that the fly has a brain, containing approximately 200,000 neurones,
and like the vertebrate central nervous system, it is composed of a
series of functionally specialized substructures. The primary sources
of sensory input are visual and olfactory, and these are processed in
the optic and antennal lobes, respectively [79]. The mushroom
bodies deal with memory [80], and the central complex provides the
motor output, once sensory integration is complete [81]. The
functional units of the brain, the neurones, are also very similar to
their human equivalents in terms of their shape, synaptic inter-
communications and their biochemical signatures. These functional
and structural similarities allow fly models of human disease to
complement the rodent paradigms at the biophysical, molecular
biological, neurobiological and behavioural levels. There are now fly
models for Huntington’s disease [55,57], a range of related polyQ
expansion disorders [82], transthyretin-linked amyloidotic poly-
neuropathy [83,84], Parkinson’s disease [85], motor neurone disease
[86] and spinal muscular atrophy [87].brain tissue suggested that mature amyloid deposits
of Ab and tau were toxic; however, three key findings
changed the opinion of many researchers in the field. First
was the finding that amyloid plaque density did not
correlate with clinical findings of AD, but instead, soluble
Ab levels [17] and tau pathology did [18]. Second was the
observation that Ab aggregates, intermediate in size
between monomeric peptide and fibrils, were particularly
toxic in cell culture and in in vitro models of synaptic
function [19–24]. Third and surprisingly, it was possible
to generate antisera that could bind the soluble aggregates
of proteins, regardless of their amino acid sequence, and
neutralize their cytotoxicity [25,26]. Notwithstanding the
toxicity ofAbfibrilsunder certain conditions [27], theweight
of evidence points to small, soluble aggregates of proteins
exerting a generic toxicity that is not entirely mediated by
specific amino acid interactions, but rather seems to rely on
shared biophysical interactions with cells [28].
In this light, a body of research indicates that the fly can
provide a faithful readout of the activity of the toxic protein
aggregates. Guided by a computational approach to pre-
dicting aggregation propensity, Luheshi and colleagues
undertook a systematic investigation of the sequence
dependency of Ab aggregation and toxicity [29–31]. To this
end, they studied the in vitro behaviour of Ab variants that
had been designed rationally to have differing propensities
to form either fibrils and/or protofibrils [7]. The neurotoxi-
city of these peptides was then tested using the fly model,
and the predicted propensity to form amyloid fibrils corre-
lated well with the in vivo toxicity, as measured by reduced
longevity and locomotor performance. However a more
satisfying correlation was shown between the predicted
propensity of Ab variants to form pre-fibrillar species and
their in vivo toxicity (Figure 2). Indeed, the investigators
were able to explain 80% of the variation in toxicity based
only on knowledge of the primary structure of the poly-
peptide [7]. Interestingly, the correlation between pheno-
typic severity and the degree of peptide aggregation seems
less strongwhenmeasuring age-related learning deficits in
Ab-expressing flies. Iijima and colleagues noted that
similar learning phenotypes were observed in flies expres-
sing Ab1-42, which exhibited peptide deposits and neuro-
degeneration, and those expressing Ab1-40, which had
structurally intact brains [32]. This result points to a role
for monomeric or very small soluble aggregates of Ab in
memory dysfunction.
The presence of such Ab aggregates induces a series of
responses that includes a transient influx of calcium and
the activation of protein kinases. There is some suggestion
that these responses might constitute an attempt by the
neurones to re-enter the cell cycle [33]; however, the result
appears to be the aberrant phosphorylation of a microtu-
bule-binding protein called tau. The appearance of tau,
phosphorylated at particular sites (as detected by specific
monoclonal antibodies) has been observed to correlate with
tau aggregation and its reduced affinity for microtubules
[34], as well as with neurodegeneration. Recently the
interaction of Ab and tau in the fly brain was modelled,
and it appears that Ab enhances phosphorylation of tau by
the wingless pathway component Shaggy (the fly ortholo-
gue of GSK3b [35]). With this report we can now aspire to a229
Figure 2. The propensity of Ab variants to form protofibrils can be quantitatively correlated with fly model phenotypes. The expression of rationally designed variants of the
Ab peptide allows the investigation of the relationship between aggregation propensity and neuronal dysfunction and death in a fly model system. Here we see that the
relative reduction in median survival (a), and impairment in locomotor performance (b) are closely correlated with the computationally-predicted propensity of peptide
variants to form protofibrils (Ztox) [7].
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in the fly brain.
What kinds of AD models have been generated in flies?
A particularly faithful invertebrate model of Ab toxicity
has been achieved by creating transgenic flies that carry
gal4-driven constructs encoding human APP and human
beta-site APP-cleaving enzyme 1 (BACE1). When
expressed in the brain, human APP is cleaved by the
transgenic human BACE1 and then by endogenous Dro-
sophila g-secretase, resulting in the generation of the Ab
peptide [36]. This relatively complex model is ideal for the
assessment of modulators of BACE1 or APP metabolism,
but, in some respects, is more cumbersome than models in
which the Ab sequence is fused downstream of a secretion
signal peptide [32,37–39]. In these latter models, the
expressed peptide has its signal peptide cleaved off as
Ab enters the secretory pathway and a proportion of the
peptide is subsequently released from the cell. However,
the degree of intracellular Ab accumulation correlates with
early phenotypes such as locomotor dysfunction [38] and
severity, and immunogold electronmicroscopy reveals that
the peptides localize to the endoplasmic reticulum (ER),
Golgi and lysosomes, but not the nucleus or mitochondria
[40]. This finding suggests that the potentially reversible
early phenotypes in AD could be mediated by the intra-
cellular accumulation and aggregation of Ab.
Although Ab-expressing flies can model one crucial
aspect of AD pathogenesis, the role of tau is also of great
importance. The tauopathies are a set of human neurode-
generative diseases related to AD, often presenting as
fronto-temporal dementia, that are characterised by
prominent intracellular accumulations of the microtubule-
binding protein tau [41]. Familial tauopathies are caused
either by deregulated mRNA splicing and the consequent
accumulation of a particular tau isoform, or alternatively by
an underlying genetic mutation [42]. Fly models allow us to
investigate the mechanism of neurodegeneration in these
tauopathies,butbyextension, theyalsoshed lightontherole
of tau in AD. The fly tauopathy models that have been230generated thus far are tau-overexpressionmodels.Although
wild type human tau is neurotoxic when overexpressed in
neuronal tissues, the rough eye and longevity phenotypes in
Drosophila model systems are more severe when disease-
relatedvariantsof tauareexpressed [43]evenwhentaudoes
not form neurofibrillary tangles [44]. Moreover, flies over-
expressing wild-type human tau can be induced to form
intracellular inclusions that resemble neurofibrillary
tangles,whenglycogensynthasekinase3b (GSK3b) activity
is increased [45]; this finding is concordant with the known
pathways of tau toxicity that seems to require hyperpho-
sphorylation of tau to speed aggregation.
Which phenotypes and surrogate markers of pathology
can be measured in fly models of AD?
Longevitymeasurement provides a statistically robust test
of the neurological integrity of a fly. Although the cause of
death is not clear, it is probably related to a combination of
behavioural deficits that impair feeding and hazard avoid-
ance [46]. We have found that the fractional increase in
median longevity as compared to control flies provides a
parameter that has validity as a comparison between, as
well as within, particular experiments [7]. However death
is the last phenotype to be exhibited by an organism, and in
a bid to accelerate data acquisition and to find experimental
readouts that resonatewith the clinical syndrome, there is a
move to quantify and automate behavioural assays in flies
(Figure 3). The most widely used behavioural assays that
are employed are Pavlovian conditioning tests of memory
and learning [32,40] and locomotor assays [32,38,46,47]
(Please see supplementary movie).
In flies, locomotor assays such as the climbing test are
popular because they need little equipment and they
measure a clear phenotype. The locomotor assay is per-
formed by placing the flies at the bottom of a tall cylinder
and allowing them a specified time to climb before the
number of flies at the top and bottom of the tube are
counted and the ratio is expressed as a performance index
[47,48]. These data give a single value for the locomotor
performance, but do not represent the full complexity of the
Figure 3. Quantifiable locomoter defects in flies expressing Ab. Flies expressing Ab peptides in their brains exhibit locomotor abnormalities (a). Computer vision and 3D
tracking of fly locomotor behaviour allows us to derive parameters that describe discriminatory features of fly locomotor behaviour. (b) The differently coloured traces
represent the tracks followed by individual flies around the inner surface of a cylindrical culture vial. The trajectories followed by healthy flies are typically straight and
oriented vertically, whereas Ab expression results in age-dependent development of abnormal movement (similar to those traces marked with red arrowheads). Such
analysis allows the early and rapid detection of the first signs of neuronal dysfunction and permits locomotor impairment to be quantified.
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are a variety of video tracking technologies being devel-
oped that give either a two dimensional view of the fly
movement [49], or track the fly in 3 dimensions [50,51]. By
tracking flies we are able to calculate which parameters,
such as maximal, mean and median velocity, best describe
and distinguish control flies from those affected by model
AD pathology. This approach will allow us to detect subtle
changes in locomotor behaviour that characterize the early
stages of neuronal dysfunction.
The rough eye phenotype is also easily recognized and
has been particularly useful in the fly tauopathy models,
where human tau expression in the retina yields adult flies
with rough, shrunken eyes [43,52]. Likewise, expression of
polypeptides containing expanded tracts of glutamine resi-
dues (polyQ), as a model of neurodegenerative diseases
similar to Huntington’s disease, results in a distinctive,
rough, de-pigmented eye [53–55]; in both cases the clarity
of the phenotypehas facilitatedgenetic screening (Figure 4).
The severity of the rough eye can be graded by a blinded
observer and has the major advantage of being essentially
fully apparent at the time of hatching (eclosion). Whereas
the rough eye is not a direct measure of neuronal integrity,
the pseudopupil assay provides an alternativeway to assess
the structural integrity of the underlying retina and follow
progressive neurodegeneration [56,57]. The pseudopupil
approach provides a quantitative measure of neurodegen-
eration, but is rather labour intensive; this property could
limit throughput for whole genome screening.
Large scale genetic screens in the study of Alzheimer’s
disease?
The use of genetic screens in the fly models of AD has been
focussed on understanding the biological pathways bywhich dysregulated Ab and tau production and aggrega-
tion might cause neuronal dysfunction and death. In the
following sections we will review what these studies have
taught us about AD pathogenesis.
Screening for genetic modifiers of Ab peptide toxicity
Genetic screening in the fly has been used to dissect the
response of the fly brain to the insult posed by Ab expres-
sion. Two such screens have been published, both in flies
expressing Ab fused downstream of a secretion signal
peptide. In the first screen, Cao and colleagues looked
for modifiers of the rough eye phenotype that accompany
Ab peptide expression [58]. Although the consequent phe-
notype is not strong (as compared to flies with excess tau or
polyQ expression) it has the advantage of being quick to
assess and has the dynamic range to allow the detection of
both enhancers and strong suppressors. The investigators
screened for dominant modifiers that resulted from, in
large part, the over-expression of genes in a library of flies
with 1963 unique insertions of mobile, transposon con-
structs (EP elements) that enhance the expression of
neighbouring genes. In the second screen, Rival and col-
leagues expressed Ab throughout the neurones, and used
changes in longevity as the primary end point [47].
Although this assay is slow to perform, with the average
fly livingmore than three weeks, the quantitative nature of
the phenotype allows for the robust statistical interpret-
ation of differences in median survival. Again the investi-
gators used EP-like elements to generate the up-regulation
of a random set of genes and were able to detect dominant
modifiers. The biological implications of the two screens
are somewhat different because, although in both cases the
Ab is expressed from early embryonic stages onwards, the
rough eye is essentially a developmental phenotype,231
Figure 4. The rough eye phenotype provides a convenient surrogate marker for neurotoxicity. The normal compound eye (a) exhibits a regular array of corneal lenses
(ommatidia) that are disrupted when toxic proteins are expressed during development. The assessment of eye roughness allows the investigator to look for modifiers of, for
example, Ab (b), tau (c) and polyQ (d) toxicity [58]. Copyright is retained by the Genetics Society of America.
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adult life.
Notably, both screens identified a role for the transition
metals copper [58] and iron [47]. Rival and colleagues used
an Affymetrix1 chip analysis to measure changes in gene
expression in response to Ab and reported that oxidative
stress was a particularly significant contributor [47]. The
most powerful modifying genes were those encoding iron-
binding proteins; of particular note were the heavy and
light chains of ferritin. Co-expression of ferritin heavy
chain and Ab suppressed the longevity and behavioural
phenotypes (Figure 5) and reduced oxidative damage
despite an increased accumulation of Ab in the brain. A
molecular dissection of the oxidative stress pathway high-
lighted the pathogenic role of the Fenton reaction in gen-
erating hydroxyl radicals. The ability of Ab to induce a Toll/
NFkB-dependent inflammatory response probably also
increases the oxidative stress experienced by neurones
[59].
Screening for genetic modifiers of human tau toxicity
Screening for modifiers of the over-expression of human
tau in fly models has been carried out by several groups.
The most widely used phenotype in such screens is the
rough eye that results from the retinal expression of wild
type and variants of human tau. As the rough appearance
is visible as soon as the adult fly hatches, this phenotype
has been adopted widely as a surrogate marker of tau
neurotoxicity.
There are, however, two main problems with the clear
interpretation of the results from screens against tau
toxicity. First, it is difficult to know exactly what toxic
gain of function we are measuring. The two likely mech-232anisms are that either abnormal tau binding to microtu-
bules causes their dysfunction or that excess unbound tau
might remain in the cytoplasm and self-associate to form
toxic aggregates. Alternatively, variant tau might trap
proteins with essential cellular functions, and it is the
loss of function of the binding partner that is the toxic
event [60]. Secondly, the various tauopathy models are
based on three or more disease-related variants of human
tau (V337M, P301L and R406W). In the fly, both Shulman
& Feany [43] and Blard and colleagues [57] have used the
tau V337M variant because it gives a milder rough eye
phenotype than either the moderate phenotype induced by
wild type tau over-expression or the more severe pheno-
types associated with R406W [61]. When these screens are
compared, each shows that the phosphorylation economy
of the cell is involved. This is particularly notable in the
work by Shulman and Feany who find that three kinases
and four phosphatases comprised the largest functional
grouping in their set of 24 modifying EP-insertion fly lines.
The precise message from this screen is complicated by the
fact that two of the kinases enhance, whereas one kinase
(par-1) suppresses, tau toxicity. Likewise, three of the
phosphatases suppress, whereas one enhances, toxicity.
The suppression of tau toxicity by par-1 is surprising given
that the human orthologue of par-1, MARK (MAP/micro-
tubule affinity-regulating kinase), binds neurofibrillary
tangles [62] and is thought to promote toxicity by specific
tau phosphorylation events [63]. One interpretation of this
discrepancy is that at concentrations of tau found in the
human brain, the par-1-mediated phosphorylation reduces
the affinity of tau for microtubules, thereby resulting in
toxicity [34]. By contrast, in the context of the over-expres-
sion of tau in animal models, tau might excessively bind
Figure 5. Genetic screens can be used to detect biological pathways thatmodulate disease-related phenotypes. Flymodels systems can be used to discover novel genes that are
involved in the expression of a disease phenotype. Following a genetic screen in flies expressing Ab it was found that co-expression of the iron-binding proteins ferritin-1HC
(dark grey) and ferritin-2LC (light grey) were the most powerful modifiers of Ab toxicity. Here the data are shown for flies expressing the highly toxic Arctic variant of Ab1-42
(E22G). The traces show that ferritin-1HC co-expression was able to significantly rescue the longevity phenotype and return the life span of Ab-expressing flies (red line) back to
almost control values (black line). Ferritin expression also rescued locomotor behaviour and oxidative stress measures back to almost wild-type levels [47].
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This argument cannot be applied to flies overexpressing
R406W tau, because they show increased toxicity when
par-1 is co-expressed; this result, however, might stem
from the atypical response of this variant to phosphoryl-
ation. Specifically R406W tau is neurotoxic in murine
model systems, despite being hypophosphorylated, in com-
parison to control mice expressing wild type human tau
[64,65].
The screen performed by Blard and colleagues [52]
identified a tyrosine phosphatase (Ptp4E) as a modifier
of tau toxicity; however phosphorylation status was not a
major functional group. Indeed, this disparity between
screens is remarkable. Blard speculated that this might
be due to differences in the screening protocol, because in
their hands, over-expression of the candidate kinases par-1
and GSK-3b yielded a rough eye phenotype, and so would
have been excluded from their analysis. The Blard screen
instead emphasised the importance of cytoskeletal com-
ponents. In particular, cheerio, the fly orthologue of the
actin-binding protein filamin, was identified as an enhan-
cer of tau pathology, in agreement with the findings of
Shulman and Feany [43]. They also showed that tau over-
expression causes morphological abnormalities in larval
neuromuscular end plates which can be rescued or
enhanced by the modifiers in the screen. This finding is
of particular interest because there is mounting evidence
that synaptic dysfunction is one of the earliest pathological
events in AD [23,66].
In both of these screens the investigators also tested
whether the modifiers of tau toxicity might have a broader
activity against protein misfolding diseases. Therefore,
they looked for modification of the eye phenotype caused
by another disease-related cytoplasmic protein. In both
cases the investigators crossed the tau-modifier lines to
flies expressing a toxic poly-glutamine expansion in
proteins that are linked to two forms of spinocerebellar
ataxia (SCA). Shulman and Feany found that their tau
modifiers, on the whole, did not have an effect on the eye
phenotype in amodel of SCA-1 [43]. By contrast, Blard and
colleagues did observe some overlap between the modifiers
of tau and polyQ phenotypes. However it appears that theshared modifiers act in distinct ways in the two model
systems. For example, the three chaperones (DnaJ-1, Csp
and Hsc70Cb) that enhanced V337M tau toxicity had a
variety of effects on their SCA-3 flies such that DnaJ-1 was
a suppressor, Csp was an enhancer, and Hsc70Cb had no
effect [52].
Concluding remarks and future perspectives
AD, like many of the common neurodegenerative diseases,
shows a high degree of heritability; indeed 60-80% of the
risk in so-called sporadic AD is genetic [67]. The existing
human genetics studies, however, have explained only half
of this risk. The main contributions are from the apolipo-
protein E [68] and clusterin loci [69,70], and to a lesser
extent from PICALM [69], CR1 [70] and SORL1 [71]. The
heritability that remains unaccounted likely stems from a
large number of genes, each of which provides a small
contribution to disease risk. The current generation of
genome-wide association studies are designed to detect
these small contributions by exhaustively linking single
nucleotide polymorphisms (SNPs) with risk for disease
across hundreds of thousands of loci per individual [68,72].
With this vast amount of data for each subject, the
statistical power of these studies is enormous, and we
are able to identify large numbers of genes that are
involved in the pathogenesis, along with some false posi-
tives. The task of prioritizing these long lists of possible
human modifier genes is labour intensive and there is a
need to focus detailed studies on those genes that have
fundamental roles to play in the disease process. Herein
could lie the next application of invertebrate model sys-
tems and of course this work will not be confined to
Drosophila. C. elegans is also a model for AD and many
other neurodegenerative diseases [73] with an equally
useful genetic toolkit [74,75]. The use of such systems
allows us to assess the pathological importance of large
numbers of possible modifier genes (several hundreds),
particularly where worm or fly orthologues exist. Genes
that are found to have a functional importance in worms
and flies, as well as showing linkage to disease in humans,
will be of particular interest for future detailed studies. This
approach has been facilitated by the whole genome-scale233
Review Trends in Biochemical Sciences Vol.35 No.4RNAi libraries now available for worms [76] and flies [77].
Any of the proposed human orthologues that showmodifier
activity in the worm can then be rapidly investigated in
Drosophilamodels prior to studies inmouse. Detailed beha-
vioural assays, increasingly assisted by automation and
computational processing of video data [50,51], will allow
us to find genes that have a phylogenetically conserved role
in mediating tau and/or Ab toxicity, and might therefore
prove to be fundamentally important steps in the pathogen-
esis of AD. Moreover, these fundamentally important gene
products will be the targets for a new generation of thera-
peutic compounds for the treatment, or even prevention, of
AD.
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